Sugi Predict
/ Targets
/ MAPK9
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to MAPK9 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma |
PHASE4 | UNKNOWN |
| Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome |
PHASE3 | COMPLETED |
| Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer |
PHASE3 | RECRUITING |
| Clinical Evaluation of the Effect of Metformin in Sepsis |
PHASE3 | UNKNOWN |
| Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility. |
PHASE3 | UNKNOWN |
| Study of ASTX029 in Subjects With Advanced Solid Tumors |
PHASE1/PHASE2 | COMPLETED |
| HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma |
PHASE1/PHASE2 | COMPLETED |
| To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. |
PHASE2 | UNKNOWN |
| Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer |
PHASE2 | COMPLETED |
| Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Dabrafenib + Trametinib + PDR001 In Colorectal Cancer |
PHASE2 | UNKNOWN |
| A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma |
PHASE1/PHASE2 | COMPLETED |
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations |
PHASE2 | RECRUITING |
| Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
PHASE2 | COMPLETED |
| Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK |
PHASE1/PHASE2 | RECRUITING |
| Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer |
PHASE1 | COMPLETED |
| A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies |
PHASE1 | RECRUITING |
| A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 |
PHASE1 | COMPLETED |
| Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia |
PHASE1 | RECRUITING |
| BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) |
PHASE1 | COMPLETED |
| Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
PHASE1 | COMPLETED |
| Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo |
nan | UNKNOWN |
| Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma |
nan | COMPLETED |
| p-AKT Expression on Clinical Outcomes in Malignant Lymphoma |
nan | COMPLETED |
| Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. |
nan | COMPLETED |
| Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage |
nan | COMPLETED |
| BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients |
nan | COMPLETED |
| Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies |
nan | RECRUITING |
| Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a MAPK9 binder may also engage these)